Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock.
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz ImmunityBio stated that it has not yet achieved median survival in patients receiving Anktiva + CAR-NK treatment in the trial.
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.
Why Is ImmunityBio Stock Back In Retail Spotlight Today? The company outlined progress across multiple cancer programs following last week's series of clinical and regulatory updates.
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.
Why ImmunityBio Stock Is Skyrocketing Again Today It has been an incredible week of positive news for ImmunityBio.
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication.
Let's uncover which stocks are experiencing notable gaps during today's session. Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline.
Heights Capital Walks From Archer Aviation: What It Means for Investors One major investor just walked away from Archer Aviation. Here’s what that move does—and doesn’t—signal for the future of urban air mobility.
